Does Wegovy Affect Your Sense of Taste?

Not a listed common side effect, but frequently reported: taste changes and altered food preferences appear in observational data and patient reports, even though they sit outside the standard gastrointestinal side-effect list in the Wegovy SmPC.
Fatty and sweet foods are most affected: people on semaglutide often describe highly palatable foods becoming less appealing or even unpleasant, which researchers link to GLP-1 receptor activity in the brain's reward pathways.
Usually temporary: for most people any taste disturbance settles as the body adjusts, particularly after the early titration weeks; persistent changes should be discussed with a prescriber.
Distinct from nausea: taste changes can occur independently of nausea — though the two often overlap, especially after a dose increase.

Wegovy (semaglutide) can change how food tastes for some people. Trial data and real-world reports both describe shifts in flavour perception, altered food preferences, and a reduced enjoyment of certain foods — particularly those that are fatty, sweet, or rich. These changes are not listed as a common side effect in the licensed product information, but they are well-recognised in clinical practice and increasingly studied. As with all aspects of Wegovy treatment, a GPhC-registered prescriber needs to assess your suitability before any prescription is issued; taste changes alone are not a reason to start or stop treatment without clinical guidance.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the science and clinical guidance say about semaglutide and taste

What clinical data actually shows about semaglutide and food preferences

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity over 68 weeks on semaglutide 2.4mg. Average body-weight fell by around 15% in the active group. The trial's primary focus was weight and cardiometabolic outcomes, so taste perception was not a pre-specified endpoint, but the weight loss itself hints at a mechanism beyond simple appetite suppression.

GLP-1 receptors are found not only in the gut and pancreas but in the brain's reward circuits, including the nucleus accumbens and the hypothalamus. Preclinical research and post-market observational data suggest that activating these receptors reduces the motivational 'pull' of calorie-dense foods. In plain terms: food that once tasted rewarding can start to taste flat, overly sweet, or simply less interesting. Some people describe a metallic edge to flavours in the early weeks of treatment.

This is meaningfully different from the GI side effects (nausea, reflux, diarrhoea) documented in the NHS medicines information on semaglutide. Those effects are directly tied to slowed gastric emptying. Taste changes appear to have a central, neurological component, which is why they can persist even when nausea has fully resolved.

The distinction matters practically. If food tastes strange early in treatment, it is often a sign the medicine is working as intended rather than a problem requiring action. Reporting any sudden, severe, or distressing changes to your prescriber is still the right call.

Which foods and flavours are most commonly affected

The pattern reported most consistently is a drop in desire for high-fat, high-sugar foods. People who previously found chocolate, fried food, or rich sauces intensely appealing often describe them as cloying or unpleasant after a few weeks on semaglutide. Alcohol is another category that many report differently, it may taste less appealing, and its effects can feel stronger, so extra caution is sensible.

Protein-rich and plant-based foods tend to be less affected, and this shift is broadly welcome from a nutritional standpoint. Protein adequacy matters on any weight-loss programme, particularly to preserve muscle mass, so a growing preference for lean meat, eggs, fish or legumes is not a bad thing.

Some people notice a temporary metallic or 'off' taste, most often in the first two to four weeks and after each dose step up. This is reported with other GLP-1 medicines too. Staying well hydrated, rinsing with plain water, and eating slowly can all help. If you are thinking about the cost side of treatment (what a private prescription actually includes and how providers compare) there is a practical breakdown on our Wegovy cost guide.

Foods with strong umami flavours (meat stocks, aged cheese, fermented foods) are often better tolerated early in treatment than sweet or fatty options. This is anecdotal but consistent enough to be a useful pointer when planning meals around the titration period.

When to mention taste changes to your prescriber

Most taste changes resolve on their own and do not need intervention. But a few situations warrant a conversation with your clinical team. If flavour disturbance is making it genuinely difficult to eat enough, particularly enough protein and vegetables, that affects nutritional balance and should be flagged. Significant unintentional weight loss, difficulty swallowing, or taste changes accompanied by persistent stomach pain are all reasons to seek advice promptly.

Severe, persistent stomach pain that radiates to the back, with or without vomiting, should be assessed urgently, this symptom pattern can indicate pancreatitis, which the MHRA highlighted in a Drug Safety Update for GLP-1 medicines. Pancreatitis is uncommon but serious, and early medical assessment matters.

Taste changes on their own, without accompanying symptoms, are very rarely a reason to stop treatment. Stopping semaglutide abruptly without prescriber guidance is not recommended. Our Wegovy treatment guide covers what to expect across the full titration journey, and our prescribers are available for aftercare questions seven days a week.

If you have noticed changes beyond taste (for instance, questions about whether semaglutide interacts with hormonal contraception or HRT) our clinical team has addressed how Wegovy may interact with HRT in a separate resource. There is also detail on loss of taste specifically and on how Wegovy affects taste buds at the receptor level for readers who want the deeper science. For questions about Wegovy and contraceptive devices, our IUD page covers the current evidence.

If you are considering starting treatment, check your eligibility with our prescribers, the consultation is free, and a named clinician reviews every application the same day.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions